Brainstorm Cell Therapeutics (NASDAQ:BCLI) Share Price Passes Above 200 Day Moving Average – Here’s What Happened

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s stock price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.86 and traded as high as $1.34. Brainstorm Cell Therapeutics shares last traded at $1.07, with a volume of 42,391 shares trading hands.

Brainstorm Cell Therapeutics Stock Down 1.9%

The stock has a market cap of $11.95 million, a price-to-earnings ratio of -0.31 and a beta of 0.28. The stock’s fifty day moving average is $1.02 and its 200-day moving average is $0.86.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last posted its earnings results on Friday, August 14th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.06). As a group, equities research analysts predict that Brainstorm Cell Therapeutics Inc. will post -3.01 earnings per share for the current fiscal year.

Brainstorm Cell Therapeutics Company Profile

BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) is a clinical?stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.

The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS).